Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States-Reference-Cited by-同舟云学术

Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States

Published:2019-08 Issue: Volume:180 Page:37-42
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Li Ang^ORCID,Manohar Poorni M.,Garcia David A.,Lyman Gary H.,Steuten Lotte M.

Funder

National Heart, Lung, and Blood Institute

Conquer Cancer Foundation

Hemostasis and Thrombosis Research Society

National Hemophilia Foundation

Publisher

Elsevier BV

Subject

Hematology

Reference21 articles.

1. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis;Prandoni;Blood,2002

2. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update;Lyman;J. Clin. Oncol.,2013

3. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial;Lee;JAMA,2015

4. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer

5. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?;Khorana;Thromb. Res.,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis;Journal of Pharmaceutical Policy and Practice;2024-07-17

2. Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis;Nature Communications;2024-07-05

3. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis;Medicina;2023-10-20

4. A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK;Current Medical Research and Opinion;2023-01-23

5. Anticoagulant Therapy for Cancer-Associated Thrombosis;Annals of Internal Medicine;2023-01